Syngene International Ltd
NSE:SYNGENE

Watchlist Manager
Syngene International Ltd Logo
Syngene International Ltd
NSE:SYNGENE
Watchlist
Price: 922.05 INR 1.26% Market Closed
Market Cap: 370B INR
Have any thoughts about
Syngene International Ltd?
Write Note

Syngene International Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Syngene International Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Syngene International Ltd
NSE:SYNGENE
Total Equity
â‚ą44B
CAGR 3-Years
13%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Total Equity
â‚ą135.7B
CAGR 3-Years
13%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Total Equity
â‚ą1.9B
CAGR 3-Years
57%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Total Equity
â‚ą57.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Tarsons Products Ltd
NSE:TARSONS
Total Equity
â‚ą6.1B
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Total Equity
â‚ą8.3B
CAGR 3-Years
79%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Syngene International Ltd
Glance View

Market Cap
369.9B INR
Industry
Life Sciences Tools & Services

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 5,975 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation and analytical development along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects, which is designed to provide a range of advance programs through target validation, translational interrogation, therapeutic discovery and preclinical development for both large and small molecules, as well as specialty modalities, such as targeted protein degradation. The company serves clients ranging from multinational corporations to start-ups.

SYNGENE Intrinsic Value
596.73 INR
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Syngene International Ltd's Total Equity?
Total Equity
44B INR

Based on the financial report for Sep 30, 2024, Syngene International Ltd's Total Equity amounts to 44B INR.

What is Syngene International Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
16%

Over the last year, the Total Equity growth was 13%. The average annual Total Equity growth rates for Syngene International Ltd have been 13% over the past three years , 16% over the past five years .

Back to Top